» Articles » PMID: 29360559

A Mapping of 115,000 Randomized Trials Revealed a Mismatch Between Research Effort and Health Needs in Non-high-income Regions

Overview
Publisher Elsevier
Specialty Public Health
Date 2018 Jan 24
PMID 29360559
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Concerns exist as to whether the allocation of resources in clinical research is aligned with public health needs. We evaluated the alignment between the effort of clinical research through the conduct of randomized controlled trials (RCTs) and health needs measured as the burden of diseases for all regions and a broad range of diseases.

Methods: We grouped countries into seven regions and diseases into 27 groups. We mapped all RCTs initiated between 2006 and 2015 that were registered at the WHO International Clinical Trials Registry Platform to regions and diseases. The burden of diseases in 2005 was mapped as disability-adjusted life years (DALYs), based on the 2010 Global Burden of Diseases study. Within regions, we defined a research gap when the proportion of RCTs concerning a disease in the region was less than half the relative burden of the disease.

Results: We mapped 117,180 RCTs planning to enroll 42.6 million patients and 2,220 million DALYs. In high- versus non-high-income countries, 130.9 versus 6.9 RCTs per million DALYs were conducted. We did not identify any research gap in high-income countries. We identified research gaps for all other regions. In particular, for Sub-Saharan Africa, we identified research gaps for common infectious diseases (CID) and neonatal disorders (ND): 5.8% (95% uncertainty interval 4.7-6.9) and 2.0% (0.9-4.5) of RCTs in Sub-Saharan Africa concerned CID and ND, although these diseases represented 22.9% and 11.6% of the burden in the region, respectively. For South Asia, we identified research gaps for the same two groups of diseases.

Conclusions: In non-high-income regions, the conduct of RCTs was misaligned with the distribution of major causes of burden, in particular infectious diseases and neonatal disorders in Sub-Saharan Africa and South Asia.

Citing Articles

Evaluating malaria burden in children under-five and intervention outcomes in Tarkwa-Nsuaem municipality.

Abdulzeid A, Bosson-Amedenu S, Gmayinaam V, Enock A, Ocloo S, Acquah J BMC Infect Dis. 2025; 25(1):294.

PMID: 40021974 PMC: 11871811. DOI: 10.1186/s12879-025-10705-z.


Characterization of clinical trials in Ecuador and their association with disease burden: Are there research gaps?.

Salgado C, Rivadeneira J, Garcia Mendez N, Manterola C J Family Med Prim Care. 2024; 13(8):2834-2840.

PMID: 39228611 PMC: 11368253. DOI: 10.4103/jfmpc.jfmpc_1181_23.


Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond.

Gieber L, Muturi-Kioi V, Malhotra S, Sitlani A Pharmaceut Med. 2023; 37(3):203-214.

PMID: 37115494 PMC: 10141866. DOI: 10.1007/s40290-023-00473-z.


Interventions for the prevention of spontaneous preterm birth: a scoping review of systematic reviews.

Campbell F, Salam S, Sutton A, Jayasooriya S, Mitchell C, Amabebe E BMJ Open. 2022; 12(5):e052576.

PMID: 35568487 PMC: 9109033. DOI: 10.1136/bmjopen-2021-052576.


Urgently seeking efficiency and sustainability of clinical trials in global health.

Park J, Grais R, Taljaard M, Nakimuli-Mpungu E, Jehan F, Nachega J Lancet Glob Health. 2021; 9(5):e681-e690.

PMID: 33865473 PMC: 8424133. DOI: 10.1016/S2214-109X(20)30539-8.